4-Ethyl-2-isopropylimidazol | 37455-59-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-Ethyl-2-isopropylimidazol
• 英文别名: 4-ethyl-2-isopropyl-1(3)H-imidazole；4-Ethyl-2-isopropylimidazole；5-ethyl-2-propan-2-yl-1H-imidazole
• CAS: 37455-59-7
• 化学式: C₈H₁₄N₂
• mdl: MFCD19221606
• 分子量: 138.213
• InChiKey: OYJZPZRULWUTKH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.625
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-Ethyl-2-isopropylimidazol 、 丙烯腈 以77%的产率得到
  参考文献：
  名称：

  YAMAUCHI M.; MASUI M., CHEM. AND IND. , 1976, NO 1, 31-32

  摘要：

  DOI：

文献信息

• [EN] COMPLEXES OF IMIDAZOLE LIGANDS<br/>[FR] COMPLEXES DE LIGANDS IMIDAZOLES
  申请人：AIR PROD & CHEM

  公开号：WO2011156699A1

  公开（公告）日：2011-12-15

  Metal imidazolate complexes are described where imidazoles ligands functionalized with bulky groups and their anionic counterpart, i.e., imidazolates are described. Compounds comprising one or more such polyalkylated imidazolate anions coordinated to a metal or more than one metal, selected from the group consisting of alkali metals, transition metals, lanthanide metals, actinide metals, main group metals, including the chalcogenides, are contemplated. Alternatively, multiple different imidazole anions, in addition to other different anions, can be coordinated to metals to make new complexes. The synthesis of novel compounds and their use to form thin metal containing films is also contemplated.

  金属咪唑酸盐配合物的描述中，描述了咪唑配体上带有大体积基团的功能化咪唑和它们的阴离子对应物，即咪唑酸盐。考虑到由一个或多个这种多烷基化咪唑阴离子配位到一种或多种金属的化合物，所述金属选自碱金属、过渡金属、镧系金属、锕系金属、主族金属，包括硫属元素。或者，可以将多种不同的咪唑阴离子以及其他不同的阴离子配位到金属上以形成新的配合物。还考虑到合成新化合物并将其用于形成含金属薄膜的用途。
• PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS
  申请人：Incyte Corporation

  公开号：US20170190689A1

  公开（公告）日：2017-07-06

  The present disclosure provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that modulate the activity of phosphoinositide 3-kinases-gamma (PI3Kγ) and are useful in the treatment of diseases related to the activity of PI3Kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

  本公开提供了化合物I的化合物，或其药用盐，其调节磷脂酰肌醇3-激酶-γ（PI3Kγ）的活性，并且在治疗与PI3Kγ活性相关的疾病方面具有用途，例如自身免疫疾病、癌症、心血管疾病和神经退行性疾病。
• Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates
  申请人：Silverback Therapeutics, Inc.

  公开号：US20200113912A1

  公开（公告）日：2020-04-16

  Methods and conjugates are disclosed for alleviating toxicity(ies) associated with administration of immune-stimulatory conjugates, and in particular for alleviating toxicity(ies) associated with intravenous administration of such conjugates.

  本发明揭示了用于减轻与免疫刺激共轭物的给药相关的毒性的方法和共轭物，并且特别用于减轻与静脉给药这类共轭物相关的毒性。
• [EN] TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS<br/>[FR] COMPOSÉS HÉTÉROBIFONCTIONNELS TRICYCLIQUES POUR LA DÉGRADATION DE PROTÉINES CIBLÉES
  申请人：C4 THERAPEUTICS INC

  公开号：WO2022081928A1

  公开（公告）日：2022-04-21

  Heterobifunctional compounds for targeted protein degradation that include a tricyclic cereblon binder linked to an appropriate protein targeting ligand to degrade a targeted disease-mediating protein of interest are provided.

  本发明提供了用于靶向蛋白降解的异双功能化合物，其中包括一个三环Cereblon结合剂，连接到一个适当的蛋白靶向配体，以降解感兴趣的靶向疾病介导蛋白质。
• Sulfonamide containing compounds for treatment of inflammatory disorders
  申请人：Weingarten M. David

  公开号：US20090270454A1

  公开（公告）日：2009-10-29

  Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of an inflammatory condition, in particular asthma. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof: wherein: X and Y are independently selected from —CH 2 — or —CH 2 —CH 2 —; Z is selected from S(O) m or Se(O) m and m is 0, 1 or 2; R 1 is optionally substituted heteroaryl or heterocyclic; R 2 is selected from the group consisting of hydrogen, C 1 -C 6 straight alkyl, and C 1 -C 6 branched alkyl, wherein all may be optionally substituted; and R 3 and R 4 are alkyl.

  提供了化合物、药物组合物及治疗或预防炎症状况，特别是哮喘的方法。该化合物属于一般式I，或其药学上可接受的盐、酯、前药或衍生物：其中，X和Y独立地选择自—CH2—或—CH2—CH2—；Z选择自S(O)m或Se(O)m，m为0、1或2；R1为可选择的取代杂环芳基或杂环基；R2选择自氢、C1-C6直链烷基和C1-C6支链烷基，其中所有基团均可选择性地取代；R3和R4为烷基。